Clin2
NCT05597280Possibly a fitRecruiting

Medicine given after exposure to prevent leprosy

Leprosy

Part of Infections clinical trials.

This Phase 3 study tests whether taking preventive antibiotics after possible contact can stop leprosy from developing. If it works, it could protect people in affected communities from getting leprosy (and possibly related infections).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
124,000 people
Ages
2 years and older
Study type
Interventional

Who can take part

  • You live in the study area clusters on Anjouan or Mohéli
  • You are age 2 or older (and not under 20 kg if you would need bedaquiline)
  • You can agree to leprosy and tuberculosis screening and the prevention medicine if you qualify
  • You should not have signs of current (active) leprosy
  • You must not have signs of active tuberculosis, in the lungs or elsewhere
  • You have not taken rifampicin or bedaquiline in the past 2 years

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06222372Recruiting
New approaches for leprosy diagnosis and treatment

This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.

Nilphamari
NCT06627257Not yet recruiting· Phase 1
Leprosy vaccine trial for healthy adults

This trial tests a new vaccine (LEP-F1 + GLA-SE) to see if it is safe and helps the body fight leprosy. It is for healthy adults living in areas where leprosy is common.

Rio de Janeiro, Rio de Janeiro
NCT06568484Recruiting· Phase 2/Phase 3
Preventing TB with bedaquiline in people exposed to TB

This study tests if bedaquiline can prevent tuberculosis (TB) in people who have been in close contact with someone with active TB, including people living with HIV. If you qualify, you would take the study medicine and be monitored to see if it prevents you from developing TB.

Ulaanbaatar
NCT07126639Not yet recruiting
Short-course treatment for drug-resistant tuberculosis

This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.

NCT07129629Not yet recruiting· Phase 2
Shorter TB treatment for drug-sensitive tuberculosis

This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.

NCT06905522Recruiting· Phase 3
Tuberculosis treatment trial for new patients

This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.

Beijing

Hear when a new Leprosy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.